Singapur - İngilizce - HSA (Health Sciences Authority)

biotronik asia pacific pte. ltd. - cardiovascular - the biotronik solia lead is only intended for the following: • permanent, transvenous implantation in the right ventricle or right atrium • use with an implantable pacemaker or a biotronik icd with pacemaker function to constitute an integrated system for permanent cardiac pacing.

Singapur - İngilizce - HSA (Health Sciences Authority)

covidien private limited - neurology - “the ev3 solitaire™ ab neurovascular remodeling device is designed for use as an adjunctive device in the treatment of intracranial aneurysms. the solitaire™ detachment system is intended for use with the solitaire™ device. the solitaire™ detachment system is not intended to be used with coils.”

Singapur - İngilizce - HSA (Health Sciences Authority)

covidien private limited - neurology - the solitaire™2 revascularization device is intended to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing ischemic stroke within 8 hours of symptom onset. patients who are ineligible for intravenous tissue plasminogen activator (iv t-pa) or who fail iv t-pa therapy are candidates for treatment.

Singapur - İngilizce - HSA (Health Sciences Authority)

covidien private limited - neurology - the solitaire™ fr revascularization device is intended to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing ischemic stroke (sfr models are indicated for use within 8 hours of symptom onset.). patients who are ineligible for intravenous tissue plasminogen activator (iv t-pa) or who fail iv t-pa therapy are candidates for treatment.the ev3 solitaire™ fr revascularization device should only be used by physicians trained in interventional neuroradiology and treatment of ischemic stroke.

Singapur - İngilizce - HSA (Health Sciences Authority)

covidien private limited - neurology - the solitaire™ platinum revascularization device is indicated for use to restore blood flow in the neurovasculature by removing thrombus for the treatment of acute ischemic stroke to reduce disability in patients with a persistent, proximal anterior circulation, large vessel occlusion, and smaller core infarcts who have first received intravenous tissue plasminogen activator (iv t-pa). endovascular therapy with the device should be started within 6 hours of symptom onset. the solitaire™ platinum revascularization device is intended to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing ischemic stroke within 8 hours of symptom onset. patients whoare ineligible for intravenous tissue plasminogen activator (iv t-pa) or who fail iv t-pa therapy are candidates for treatment.

Singapur - İngilizce - HSA (Health Sciences Authority)

covidien private limited - neurology - the solitaire™ x revascularization device is designed for use in the flow restoration of patients with ischemic stroke due to large intracranial vessel occlusion. patients who are ineligible for intravenous tissue plasminogen activator (iv t-pa) or who fail iv t-pa therapy are candidates for treatment. the solitaire™ x revascularization device should only be used by physicians trained in interventional neuroradiology and treatment of ischemic stroke

Filipinler - İngilizce - FDA (Food And Drug Administration)

euro generics international phils., inc. - ursodeoxycholic acid - tablet, film coated - 300mg

Filipinler - İngilizce - FDA (Food And Drug Administration)

euro generics international phils., inc. - ursodeoxycholic acid - tablet, film coated - 150mg

Ürdün - İngilizce - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

الشركة المتحدة لصناعة الأدوية - united pharmaceutical manufacturing co. ltd. - duloxetine hcl 33.68 milligram - 33.68 milligram

Ürdün - İngilizce - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

الشركة المتحدة لصناعة الأدوية - united pharmaceutical manufacturing co. ltd. - duloxetine 60 mg - 60 mg